Table 2. Overview of TEAEs and most common TEAEs (occurring in ≥ 2 patients) in patients with POS with/without SGS by perampanel dose (Safety Analysis Set)[a]

	4 mg (n=45)	6 mg (n=28)	8 mg (n=12)	10 mg (n=2)	12 mg (n=1)	Total (N=88)
Any TEAE, n (%)	35 (77.8)	21 (75.0)	7 (58.3)	1 (50.0)	1 (100.0)	65 (73.9)
Most common TEAEs (≥ 2 patients, n (%)						
Dizziness	25 (55.6)	11 (39.3)	6 (50.0)	1 (50.0)	0 (0.0)	43 (48.9)
Somnolence	3 (6.7)	5 (17.9)	2 (16.7)	0 (0.0)	0 (0.0)	10 (11.4)
Headache	4 (8.9)	3 (10.7)	0 (0.0)	0 (0.0)	0 (0.0)	7 (8.0)
Dysarthria	2 (4.4)	1 (3.6)	1 (8.3)	0 (0.0)	0 (0.0)	4 (4.5)
Seizure	0 (0.0)	2 (7.1)	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.3)
Fatigue	2 (4.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.3)
Pruritus	2 (4.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.3)
Serious TEAEs, n (%)	3 (6.7)	2 (7.1)	0 (0.0)	0 (0.0)	1 (100.0)	5 (5.7)
TEAEs leading to discontinuation, n (%)	4 (8.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4 (4.5)

POS, partial-onset seizures; SGS, secondarily generalized seizures; TEAE, treatment-emergent adverse event

[a]Patients from SAS where dose data are available; 88 patients were included in the dose analysis subset of the SAS